ANTIVIRAL TREATMENT IN PATIENTS WITH INFLUENZA INFECTION: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/cpzr5184Keywords:
Influenza Infection, Antiviral TreatmentAbstract
Introduction: Influenza is a viral infection which is characterized by fever, cough, and runny nose. Influenza may cause a disease in varying degrees, mild to severe. Influenza is a self-limiting disease, however, patients with comorbidities may experience severe sequelae. Due to this, antiviral agents are very crucial for influenza patients.
Objective: This article aims to discuss treatment agents for influenza patients.
Methods: This manuscript was prepared based on Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020. PRISMA is the basis of determining the criteria used in conducting this systematic review. The desired result is a patency comparison between the two techniques. The articles included should be published between 2013 until 2023. The keywords used in search strategy were "antiviral" and "influenza".
Results: The results were presented in Table 1. 267 articles from PubMedn and 212 articles from SagePub were obtained from initial search. The final screening process resulted in 10 publications.
Conclusion: Research showed that baloxavir was more effective than NAI, while NAI was more effective than placebo. Baloxavir had more severe side effects compared to NAI, though both drugs were safe for children.
References
Prince HE, Leber AL. Comparison of complement fixation and hemagglutination inhibition assays for detecting antibody responses following influenza virus vaccination. Clin Vaccine Immunol. 2003;10(3):481–2.
Ranuh IGN; Suyitno H; Hadinegoro SRH; et al. Pedoman Imunisasi di Indonesia. Jakarta: Ikatan Dokter Anak Indonesia (IDAI); 2015.
Kosasih H, Klimov A, Xiyan X, Lindstrom S, Mahoney F, Beckett C, et al. Surveillance of influenza in Indonesia, 2003–2007. Influenza Other Respi Viruses. 2013;7(3):312–20.
Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2019–20 influenza season. MMWR Recomm reports. 2019;68(3):1.
Kumar D, Ison MG, Mira J-P, Welte T, Hwan Ha J, Hui DS, et al. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect Dis. Mei 2022;22(5):718–30.
Hayden FG, Lenk RP, Stonis L, Oldham-Creamer C, Kang LL, Epstein C. Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials. J Infect Dis. November 2022;226(10):1790–9.
Butler CC, van der Velden AW, Bongard E, Saville BR, Holmes J, Coenen S, et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet (London, England). Januari 2020;395(10217):42–52.
Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. Oktober 2020;20(10):1204–14.
Baker J, Block SL, Matharu B, Burleigh Macutkiewicz L, Wildum S, Dimonaco S, et al. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). Pediatr Infect Dis J. Agustus 2020;39(8):700–5.
Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. September 2018;379(10):913–23.
Beigel JH, Bao Y, Beeler J, Manosuthi W, Slandzicki A, Dar SM, et al. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis. Desember 2017;17(12):1255–65.
Bradley JS, Blumer JL, Romero JR, Michaels MG, Munoz FM, Kimberlin DW, et al. Intravenous Zanamivir in Hospitalized Patients With Influenza. Pediatrics. November 2017;140(5).
Ison MG, Fraiz J, Heller B, Jauregui L, Mills G, O’Riordan W, et al. Intravenous peramivir for treatment of influenza in hospitalized patients. Antivir Ther. 2014;19(4):349–61.
de Jong MD, Ison MG, Monto AS, Metev H, Clark C, O’Neil B, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis an Off Publ Infect Dis Soc Am. Desember 2014;59(12):e172-85.
Ng KE. Xofluza (Baloxavir Marboxil) for the Treatment Of Acute Uncomplicated Influenza. P T. Januari 2019;44(1):9–11.
Centers for Disease Control and Prevention National Center for Health Statistics. Influenza Antiviral Medications: Summary for Clinicians. Antiviral Drugs. 2020.
US Food and Drug Administration. Oseltamivir Phosphate. Washington DC; 1999.
US Food and Drug Administration. Oseltamivir. Drug Information. 2019.
Cavalcante MB, Cavalcante CTMB, Braga ACS, et al. COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding. Geburtshilfe Frauenheilkd. 2021;81(1):46–60.
Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan H, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. J Penyakit Dalam Indones. April 2020;7(1):45.
Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv [Internet]. 1 Januari 2020;2020.03.17.20037432.Available in : http://medrxiv.org/content/early/2020/04/15/2020.03.17.20037432.abstract
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Advanced Research in Medical and Health science (ISSN 2208-2425)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
